Abstract
Cited rationale for variance in use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian, fallopian tube, and primary peritoneal carcinoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have